PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit. Today, we are discussing the VISIBLE trial, recently published in JAMA Dermatology, which addresses improving diversity in psoriasis clinical trials. Seth, this topic has been long overdue, hasn’t it?
Seth: Absolutely, Britany. Psoriasis affects approximately two to three percent of the global population, yet patients with skin of color—particularly those with Fitzpatrick skin types four through six—often experience diagnostic delays and treatment disparities. These challenges contribute to worse clinical outcomes. Despite this, most clinical trials have predominantly enrolled White participants, which limits the generalizability of their findings.
Britany: Exactly. This underrepresentation perpetuates health inequities. The VISIBLE trial aimed to change that by enrolling over fifty percent of participants with Fitzpatrick skin types four to six, marking a significant shift from prior studies.
Seth: What makes the VISIBLE trial particularly innovative is its dual approach to assessing skin tone. They combined objective colorimetry with self-reported race and ethnicity. This method improves precision and inclusivity, addressing the inconsistent skin tone reporting that has plagued past trials.
Britany: Beyond recruitment, the trial also focused on retention by implementing culturally competent strategies. These included tailored communications and staff training designed to better engage communities with skin of color. It was a comprehensive approach that went beyond simply ticking diversity boxes.
Seth: Recruitment and retention often fail because of cultural, socioeconomic, and systemic barriers. The VISIBLE framework integrates solutions directly into the trial design to overcome these challenges.
Britany: Regarding methodology, this was a randomized clinical trial that embedded a diversity-focused quality improvement framework. The investigators focused on recruitment and retention metrics alongside traditional clinical endpoints.
Seth: They enrolled 211 adults with moderate-to-severe plaque psoriasis across multiple sites in the United States, specifically targeting skin of color communities. Impressively, they achieved enrollment seven times faster than historical psoriasis trials.
Britany: The inclusion criteria were adults aged eighteen years or older with clinically diagnosed moderate-to-severe plaque psoriasis who were willing to participate in skin tone assessments and biomarker sampling. Exclusion criteria included contraindications to guselkumab or other biologic therapies and inability to comply with study procedures.
Seth: The intervention was guselkumab, dosed according to Food and Drug Administration approval. This was not a placebo-controlled trial; the primary focus was on diversity and recruitment metrics alongside clinical outcomes.
Britany: Guselkumab is an interleukin-23 inhibitor that has demonstrated robust efficacy in psoriasis. However, prior trials lacked sufficient representation of patients with skin of color. The VISIBLE trial fills this important gap.
Seth: The trial confirmed guselkumab’s efficacy and safety across all skin tones, including Fitzpatrick types four through six. This supports its broad applicability and gives clinicians greater confidence when treating diverse patient populations.
Britany: One methodological advance was the use of colorimetry as an objective tool to assess skin tone and treatment response. Optical assessments help standardize measurements of erythema and pigmentation, which can vary significantly in darker skin.
Seth: Traditional visual assessments often underestimate inflammation in skin of color, so objective tools like colorimetry improve accuracy and help avoid misclassification of disease severity or treatment response.
Britany: The trial also collected biomarker data relevant to skin of color populations, paving the way for personalized dermatology approaches.
Seth: Integrating biomarkers helps us understand pathophysiologic differences across racial and ethnic groups, which can influence the efficacy and safety profiles of therapies such as guselkumab.
Britany: Their culturally competent recruitment efforts resulted in one hundred percent non-White enrollment, with over half of participants having Fitzpatrick skin types four through six—a remarkable achievement.
Seth: Tailored communications and culturally sensitive staff training enhanced retention and data quality. This aligns with evidence that culturally tailored recruitment improves diverse participation in clinical trials.
Britany: Seth, what do you see as the clinical implications of these findings?
Seth: Clinicians should recognize that guselkumab is effective across diverse skin tones, supporting its use in patients with skin of color. Additionally, when interpreting trial data, it is important to consider whether the study population reflects the diversity of your own patient population.
Britany: From a research perspective, future trials should adopt dual skin tone assessments and culturally competent recruitment frameworks like those used in VISIBLE to improve data quality and applicability.
Seth: Another important consideration is monitoring for potential drug interactions with guselkumab, especially in patients with comorbidities who require multiple medications. While guselkumab has a favorable safety profile, vigilance remains warranted.
Britany: Special populations, such as patients with psoriatic arthritis, were not the focus of this trial. Future research should explore guselkumab’s safety and efficacy in diverse cohorts with psoriatic arthritis.
Seth: It is also worth noting that the VISIBLE trial’s sample size was smaller and enrollment period shorter than larger phase three studies, which limits insights into long-term retention and outcomes. While the findings are promising, they should be interpreted within this context.
Britany: Nevertheless, the trial provides a replicable model for improving diversity in dermatologic clinical trials—a major step forward.
Seth: Related studies support these findings. For example, Alexis and colleagues confirmed guselkumab’s efficacy across skin tones with rapid clearance, reinforcing the conclusions of the VISIBLE trial.
Britany: Bhutani’s phase three B study demonstrated sustained quality of life benefits in skin of color cohorts using culturally sensitive recruitment methods, complementing the VISIBLE trial’s approach.
Seth: Ritchlin’s psoriatic arthritis trial showed durable disease control with guselkumab but lacked an explicit focus on diversity, highlighting the need for more inclusive future studies.
Britany: To summarize, the VISIBLE trial embeds multifaceted diversity strategies into a randomized clinical trial, validates guselkumab’s efficacy and safety in a fully diverse cohort, and introduces objective skin tone assessments to improve trial quality.
Seth: It demonstrates that culturally competent recruitment and retention can accelerate enrollment and improve data quality, setting a new standard for clinical trial design.
Britany: For clinicians, this means greater confidence in applying trial data to diverse patients and advocating for inclusive research.
Seth: For researchers, it provides a blueprint for integrating diversity as a core component of trial design rather than an afterthought.
Britany: Thank you for this insightful discussion, Seth. The VISIBLE trial exemplifies how intentional design advances equity and quality in dermatologic research.
Seth: Thank you, Britany. I look forward to seeing how this framework influences future studies and improves care across diverse populations.
Britany: That wraps up today’s PACULit update. The full study is available on PubMed with the identification number 39661358. Stay tuned for more literature updates advancing clinical pharmacy and medical practice.
Seth: Until next time, keep pushing evidence-based care with inclusivity at the forefront.
Britany: Absolutely. Take care, everyone.
Seth: Before we close, Britany, I want to emphasize the importance of ongoing education for healthcare providers. Understanding the nuances of skin of color in dermatology is crucial—not just for psoriasis but for many conditions where presentation differs by pigmentation.
Britany: That is a great point, Seth. Medical curricula often lack sufficient training on skin of color, which contributes to diagnostic delays and mismanagement. Incorporating findings from trials like VISIBLE into continuing education can help bridge that gap.
Seth: Exactly. Beyond education, healthcare systems should support access to treatments like guselkumab for underserved populations. Insurance coverage and affordability remain barriers that can undermine the benefits demonstrated in these trials.
Britany: Addressing social determinants of health is essential to translate clinical trial advances into real-world outcomes. Community engagement and patient advocacy must go hand in hand with scientific progress.
Seth: Well said. The VISIBLE trial is a step forward, but it is part of a larger movement toward health equity. We all have a role in ensuring that diversity in research leads to equitable care in practice.
Britany: Could not agree more. Thanks again for this enriching conversation, Seth.
Seth: My pleasure, Britany. Looking forward to our next discussion.
Britany: And thank you to our listeners for joining us on PACULit. Remember, advancing medicine means advancing inclusivity. See you next time.